Discovery soars on FDA specifications nod for Surfaxin
This article was originally published in Scrip
Executive Summary
Shares of Discovery Laboratories went on a 54% rocket ride on 4 October after the firm revealed the US FDA had agreed to updated product specifications for Surfaxin (lucinactant) intratracheal suspension – a drug approved last year but was grounded with manufacturing issues.